{
  "relevance_rule": {
    "rule_text": "All abstracts that have client provided keywords",
    "approach": "keywords",
    "key_concepts": {
      "keywords": [
        "Hyperphosphatemia",
        "Parathyroid hormone",
        "Calcitriol",
        "Chronic kidney disease",
        "ESRD",
        "Phosphate binder",
        "Sevelamer",
        "sucroferric oxyhydroxide",
        "lanthanum carbonate",
        "Ferric citrate",
        "Calcium acetate",
        "Constipation",
        "Tenapanor",
        "Claudins",
        "FGF receptor",
        "Albuminuria",
        "nicotinamide",
        "vitamin D",
        "SGLT2 inhibitors",
        "canagliflozin",
        "Dapagliflozin",
        "Empagliflozin",
        "Ozempic",
        "Calcium carbonate",
        "Serum phosphate",
        "Phosphate",
        "Fibroblast growth factor 23",
        "Hemodialysis",
        "Dialysis",
        "Dialysis Outcomes and Practice Patterns Study",
        "Sodium hydrogen transport exchanger 3",
        "sodium-dependent phosphate cotransporter 2b",
        "KDIGO",
        "KDOQI",
        "Sodium",
        "Phosphorus",
        "Klotho",
        "Tight junctions",
        "Occludins",
        "Vascular calcification",
        "Bristol Stool Form Scale",
        "Interdialytic weight gain",
        "peritoneal dialysis",
        "NTX1942",
        "SLC34A2",
        "Glomerular",
        "CKD-MBD",
        "Smooth muscle calcification",
        "Oxylanthanum carbonate"
      ],
      "categories": [],
      "contextual_concepts": []
    },
    "reasoning": "Explicitly stated as the relevance rule and matches the guideline for relevance filter using client provided keywords."
  },
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Phase 2 data, Phase 3 data (including meta-analyses), real-world data (including PROs and registry data), Phosphate binders/phosphate lowering treatment; EXCLUDE Ardelyx sponsored abstracts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 2",
          "Phase 3",
          "meta-analysis",
          "real-world data",
          "PROs",
          "registry data",
          "Phosphate binder",
          "phosphate lowering treatment"
        ],
        "categories": [
          "Clinical trial phase",
          "Treatment type"
        ],
        "contextual_concepts": [
          "meta-analyses",
          "patient reported outcomes",
          "registry data"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored"
      ],
      "reasoning": "Requires both keyword matching for phases and treatments, and context for real-world data and meta-analyses. Excludes Ardelyx sponsored abstracts to ensure mutual exclusivity with Internal priority."
    },
    {
      "priority": "Internal",
      "rule_text": "Ardelyx sponsored abstracts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ardelyx sponsored"
        ],
        "categories": [
          "Sponsorship"
        ],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "Can be identified by keyword matching for sponsorship. Mutually exclusive with High priority by exclusion."
    },
    {
      "priority": "Medium",
      "rule_text": "Phase 1 data, retrospective analyses, prognostic studies, trial designs, preclinical studies; studies with trial outcomes and endpoints; other general studies; EXCLUDE Ardelyx sponsored abstracts and all High priority concepts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 1",
          "retrospective analysis",
          "prognostic study",
          "trial design",
          "preclinical study",
          "trial outcomes",
          "endpoints"
        ],
        "categories": [
          "Clinical trial phase",
          "Study type"
        ],
        "contextual_concepts": [
          "general studies"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase 3",
        "meta-analysis",
        "real-world data",
        "PROs",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment"
      ],
      "reasoning": "Requires both keyword and context matching for study types and outcomes. Excludes Ardelyx sponsored and all High priority concepts for mutual exclusivity."
    },
    {
      "priority": "Low",
      "rule_text": "All abstracts that only have mention of an indication and does not include any other data; EXCLUDE all higher priority concepts",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [
          "Indication only"
        ],
        "contextual_concepts": [
          "no data",
          "no study results",
          "no endpoints",
          "no trial phase"
        ]
      },
      "exclusions": [
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "meta-analysis",
        "real-world data",
        "PROs",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment",
        "Ardelyx sponsored",
        "retrospective analysis",
        "prognostic study",
        "trial design",
        "preclinical study",
        "trial outcomes",
        "endpoints"
      ],
      "reasoning": "Requires semantic/contextual analysis to determine if only indication is mentioned and no other data is present. Excludes all higher priority concepts for mutual exclusivity."
    }
  ]
}